Introduction
Bladder cancer is one of the most common genitourinary malignancies, with approximately 429,800 new cases and 165,100 deaths annually worldwide (1) . Bladder cancer is categorized into 2 groups based on its distinct behavior: low-grade nonmuscle-invasive bladder cancer (NMIBC) and high-grade muscle-invasive bladder cancer (MIBC). NMIBC is the most common presentation of bladder cancer and is often treatable by endoscopic resection and intravesical therapy. However, the probability of death from MIBC with LN metastasis is markedly higher than that from MIBC without LN metastasis. The death rate increases from 18.6% to 77.6% within 5 years, even when the MIBC is treated with radical cystectomy (2, 3) , and LN-metastatic MIBC patients with extranodular extensions have an even worse prognosis (hazard ratio: 2.01) (4) . Multiple independent studies have demonstrated that LN metastasis is a key prognostic factor in bladder cancer (3, 5, 6) .
LN metastasis is a complex multistep process that involves intratumoral and peritumoral lymphangiogenesis, dissemination of tumor cells to lymphatic vessels, transport of tumor cells to LNs through the lymphatic system, and settlement and colonization expansion of tumor cells in LNs (7, 8) . It has been verified that lymphangiogenesis, which is correlated with LN metastasis and metastasis-free survival in bladder cancer, is a necessary step for LN metastasis of human cancer (9) (10) (11) . Accumulating evidence has shown that upregulated VEGF-C, a lymphangiogenic growth factor, positively correlates with regional LN metastasis and poor survival in multiple human malignancies, including bladder cancer (9, (11) (12) (13) (14) (15) . Several groups have reported that when VEGF-C signaling is blocked via either small interfering RNAs or a neutralizing antibody to VEGF-C or VEGF-R3, the lymphatic-based metastatic spread of human malignancies can be inhibited (9, (16) (17) (18) . Importantly, the VEGF-C monoclonal antibody (VGX-100) has been tested in a phase I clinical trial for advanced or metastatic solid tumors that are refractory to standard treatments (ClinicalTrials.gov NCT01514123). Therefore, understanding the regulatory mechanisms of VEGF-C in bladder cancer may provide clinically valuable predictive tools for effective anti-VEGF-C treatments.
Long noncoding RNAs (lncRNAs), defined as transcripts that are larger than 200 nt with no protein-coding capacity, play diverse roles in the development and progression of human cancers (19) . For example, HOTAIR, SChLAP1, and BLACAT1 participate in the metastatic cascade by promoting cell migration and invasion (20) (21) (22) , and lncRNA-ATB and LINC01186 contribute to metastasis by inducing epithelial-mesenchymal transition (EMT) (23, 24) . However, the precise mechanisms of lncRNAs in lymphangiogenesis remain unknown.
Herein, we identified an lncRNA LINC00958, which we termed bladder cancer-associated transcript 2 (BLACAT2), which was markedly overexpressed in LN-metastatic bladder cancer. Overexpression of BLACAT2 promoted bladder cancer-associated lymphangiogenesis and lymphatic metastasis both in vitro and in vivo. Importantly, blocking VEGF-C signaling with a VEGF-C antibody dramatically reduced LN metastasis of high BLACAT2-expressing bladder cancers in vivo. Therefore, our results indicate that BLACAT2 plays a crucial role in lymphangiogenesis and lymphatThe prognosis for bladder cancer patients with lymph node (LN) metastasis is dismal and only minimally improved by current treatment modalities. Elucidation of the molecular mechanisms that underlie LN metastasis may provide clinical therapeutic strategies for LN-metastatic bladder cancer. Here, we report that a long noncoding RNA LINC00958, which we have termed bladder cancer-associated transcript 2 (BLACAT2), was markedly upregulated in LN-metastatic bladder cancer and correlated with LN metastasis. Overexpression of BLACAT2 promoted bladder cancer-associated lymphangiogenesis and lymphatic metastasis in both cultured bladder cancer cell lines and mouse models. Furthermore, we demonstrate that BLACAT2 epigenetically upregulated VEGF-C expression by directly associating with WDR5, a core subunit of human H3K4 methyltransferase complexes. Importantly, administration of an anti-VEGF-C antibody inhibited LN metastasis in BLACAT2-overexpressing bladder cancer. Taken together, these findings uncover a molecular mechanism in the lymphatic metastasis of bladder cancer and indicate that BLACAT2 may represent a target for clinical intervention in LN-metastatic bladder cancer.
Long noncoding RNA BLACAT2 promotes bladder cancer-associated lymphangiogenesis and lymphatic metastasis here termed BLACAT2, was significantly upregulated in highgrade MIBC tissues compared with paired adjacent normal tissues ( Figure 1A) . Furthermore, quantitative reverse-transcription PCR (RT-qPCR) analysis showed that BLACAT2, which was examined in a larger 140-case cohort of bladder cancers, was overexpressed in high-grade bladder cancer compared with lower-grade tumor, in LN-positive bladder cancer compared with LN-negative tumor, and in LN-metastatic tumors compared with matched primary tumors ( Figure 1B and Supplemental Figure 1, A and B) . This result was further confirmed by analyses of The Cancer Genome Atlas (TCGA) database (Supplemental Figure 1C) . Moreover, statistical analysis revealed that BLACAT2 expression was not only strongly correlated with pathological grade (P < 0.001), but was also associated with the LN metastasis status of bladder cancer (P < 0.05) (Supplemental Table 2 ). Furthermore, patients with high BLACAT2-expressing bladder cancers had shorter overall and ic metastasis, and our data highlight a regulatory mechanism for VEGF-C and LN metastasis in bladder cancer.
Results

BLACAT2 overexpression correlates with LN metastasis of bladder cancer.
To identify critical lncRNAs that contribute to bladder cancer progression, high-grade MIBC and paired adjacent normal tissues from 3 patients were subjected to an lncRNA microarray analysis. The patient characteristics are shown in Supplemental Table 1 (supplemental material available online with this article; https://doi.org/10.1172/JCI96218DS1). As shown in Figure 1A , the microarray analysis identified 158 upregulated and 142 downregulated lncRNAs from 7,419 analyzed lncRNAs in the MIBC tissues, including CASC9, MIAT, MEG3, and LINC01133, which are associated with human cancer progression (25) (26) (27) (28) . Additionally, one lncRNA (LINC00958, RefSeq accession number NR_038904), Figure 1 . BLACAT2 overexpression correlates with LN metastasis and poor prognosis of bladder cancer. (A) Unsupervised hierarchical clustering of lncRNAs that are differentially expressed in MIBC and paired normal adjacent tissues (NAT) (fold changes > 2.0, P < 0.05). The red color scale (log 2 fold change) represents a higher expression level, and the green color scale represents a lower expression level. (B) RT-qPCR analysis of BLACAT2 expression in a 140-case cohort of freshly collected human bladder cancer samples with or without LN metastasis. The nonparametric Mann-Whitney U test was used to compare the expression levels of the 2 groups. (C) Negative correlation between BLACAT2 expression and survival in the patient cohort referred to in B. The Kaplan-Meier method was used to estimate survival for the 2 groups. Median BLACAT2 expression was used as a cutoff value. (D and E) Representative images (left panels) and percentages (right panels) of tissue specimens with high and low levels of LYVE1-positive intratumoral (D) and peritumoral (E) microlymphatic vessels in 140 cases of bladder cancer with low or high expression of BLACAT2. BLACAT2 expression levels were quantified by ISH, and microlymphatic vessel density was quantified by immunohistochemistry using the anti-LYVE1 antibody. Two representative cases are shown. Statistical significance was assessed by χ 2 test. Scale bars: 50 μm (D and E). **P < 0.01. jci.org Volume 128 Number 2 February 2018 localized to the nuclei of bladder cancer cells (Supplemental Figure 3, E and F). BLACAT2 level correlates with the intratumoral and peritumoral lymphatic vessel density. Tumor-associated lymphangiogenesis, which is an independent prognostic factor in bladder cancer, is associated with LN metastasis (12, 29) . Importantly, statistical analysis revealed that BLACAT2 expression was significantly correlated with microlymphatic vessel density (MVD), as indicated by LYVE-1-positive microvessels in both the intratumoral and the peritumoral regions of bladder cancers (P < 0.001 and P < 0.001, respectively), suggesting that BLACAT2 may play a vital role in lymphangiogenesis in bladder cancer (Figure 1, D and E) .
BLACAT2 promotes LN metastasis in vivo. To investigate the role of BLACAT2 in LN metastasis, UM-UC-3/luc and HT-1376/ luc bladder cancer cell lines were established to stably overexpress BLACAT2 or an shRNA targeting BLACAT2 (Supplemental Figure 4 , A and B). These cells were implanted into the footpads of nude mice (Supplemental Figure 4C) . Strikingly, the volumes of the popliteal LNs were dramatically larger in the BLACAT2/ mice, but smaller in the BLACAT2 shRNA/mice, than those in the corresponding control mice (Figure 2A and Supplemental Figure 5A ). Immunostaining of luciferase confirmed that forced metastasis-free survival ( Figure 1C and Supplemental Figure 1D ), suggesting a potential link between a high BLACAT2 expression level and human bladder cancer progression.
Interestingly, analyses of TCGA and GEO databases showed that BLACAT2 expression was also significantly upregulated in multiple types of human cancer, such as lung cancer, thyroid cancer, liver cancer, and glioma (Supplemental Figure 2 , A-G), and higher expression of BLACAT2 correlated with poor prognosis in glioma (Supplemental Figure 2H) , further supporting the oncogenic role of BLACAT2 in cancer.
BLACAT2 is located on human chromosome 13p15.2 (Supplemental Figure 3A ). In our assessment, the full-length BLACAT2 transcript was 1120 nt in the bladder cancer cell lines, which were examined using the 5′ and 3′ rapid amplification of cDNA end (RACE) method (Supplemental Figure 3 , B and C).
Consistent with the results obtained by RT-qPCR, an in situ hybridization (ISH) analysis showed that BLACAT2 expression was mildly detectable in normal bladder tissues and moderately expressed in non-LN-metastatic bladder cancer tissues; however, BLACAT2 was strongly upregulated in LN-metastatic bladder cancer (Supplemental Figure 3D) . Both the ISH analyses and the subcellular fractionation assay indicated that BLACAT2 mainly 
BLACAT2 induces lymphangiogenesis in vivo and in vitro.
Because lymphangiogenesis is a rate-limiting step for LN metastasis of bladder cancer (10, 11), we further examined whether BLA-CAT2 overexpression promotes lymphangiogenesis in the animal model. Importantly, the quantity of intratumoral and peritumoral lymphatic vessels in the primary tumors, which were assessed using an antibody to a lymphatic marker, LYVE-1, were dramatically increased in mice bearing the BLACAT2-transduced cells and decreased in the mice transplanted with BLACAT2-silenced cells ( Figure 3A ), indicating that BLACAT2 promotes lymphangiogenesis in vivo.
Next, we further evaluated the effect of BLACAT2 overexpression on the promotion of lymphangiogenesis in vitro. Tube formation assays showed that the conditioned medium from the BLACAT2-transduced bladder cells strongly provoked tube formation by human lymphatic endothelial cells (HLECs), whereas BLACAT2 silencing abolished the ability of bladder cancer cells expression of BLACAT2 significantly promoted the metastatic capability of bladder cancer cells to LNs and that ablation of BLACAT2 inhibited LN metastasis ( Figure 2B and Supplemental Figure 5B ), as determined by the number of metastatic LNs (Supplemental Figure 6A) . The tumor/BLACAT2-bearing mice had shorter survival times, and the tumor/BLACAT2 shRNAbearing mice had longer survival times (Supplemental Figure  6B ). Meanwhile, we observed only small volume alterations of xenografted tumors in the footpads of nude mice between mice with high BLACAT2 expression and those with low BLA-CAT2 expression (Supplemental Figure 7A) , and the number and distribution of metastatic foci in lung were higher in BLA-CAT2-overexpressing groups than in the control group, suggesting that the reason BLACAT2-overexpressing mice died earlier was distant metastasis (Supplemental Figure 7B ). Taken together, these results indicate that BLACAT2 plays a critical role in LN metastasis of bladder cancer in vivo. tissues, while the control tumors exhibited sharp edges ( Figure 4A ), suggesting that overexpression of BLACAT2 may augment the invasive ability of bladder cancer cells. Next, wound healing and Transwell cell migration/invasion assays revealed that ectopic expression of BLACAT2 significantly enhanced the motility (Supplemental Figure 9 , A-D) and invasiveness (Supplemental Figure 10 , A and B) of bladder cancer cells, whereas the opposite outcome was observed after BLACAT2 depletion. Moreover, 3D epithelial Matrigel culture models, which mimic the process of tumor invasion of the basement membrane, showed that BLACAT2 overexpression accelerated bladder cancer cell invasion, whereas BLACAT2 ablation drastically suppressed the invasive capability of the bladder cancer cells (Supplemental Figure 10C ). These results also suggested that BLACAT2 may to induce HLEC tube formation ( Figure 3 , B and C). Additionally, Transwell migration assays revealed that the migratory speed of HLECs was dramatically increased in the conditioned medium of BLACAT2-transduced cells, but decreased in the BLACAT2-silenced conditioned medium (Supplemental Figure 8 , A and B). Therefore, our results suggest that BLACAT2 overexpression induces lymphangiogenesis in vivo and in vitro.
BLACAT2 promotes metastasis of bladder cancer cells. LN metastasis is a complex multistep process (30) . In addition to intratumoral and peritumoral lymphangiogenesis, enhanced cell invasion and extracellular matrix degradation are essential for metastasis (31, 32) . Importantly, we noticed that the tumors formed by the BLACAT2-transduced bladder cancer cells grown in the footpads of the nude mice displayed spike-like structures that invaded the surrounding be involved in the EMT of bladder cancer cells. As expected, the RT-qPCR, immunoblotting, and immunofluorescence analyses revealed that E-cadherin, an epithelial marker, was downregulated, whereas the expression levels of N-cadherin, vimentin, and fibronectin, which are mesenchymal markers, were increased in BLACAT2-overexpressing cells (Supplemental Figure 11 , A-F). Consistently, BLACAT2 silencing dramatically reversed the TGF-β-induced mesenchymal feature of the UM-UC-3 and 5637 bladder cancer cell lines (Supplemental Figure 11 , B-F). Furthermore, we found that depletion of BLACAT2 in UM-UC-3 cells, which represents a mesenchymal phenotype at baseline, significantly downregulated mesenchymal biomarkers, such as fibronectin and vimentin (Supplemental Figure 12, A and B) . Additionally, tail-vein assays showed that BLACAT2 overexpression expanded the metastatic bladder cancer cell colonization of the lung (Figure 4 , B and C), whereas BLACAT2 silencing strongly decreased lung colonization by tumor cells (Figure 4 , D and E). Collectively, these results indicate that BLACAT2 increases the invasiveness of bladder cancer cells both in vitro and in vivo.
BLACAT2 regulates VEGF-C, SNAI2, and MMP9 expression.
To explore the molecular mechanisms underlying BLACAT2-induced lymphatic metastasis in bladder cancer, we profiled BLACAT2-silenced UM-UC-3 cells and control cells using next-generation sequencing (NGS). Among 1,384 genes that were regulated by BLACAT2 (P < 0.05, fold changes > 2.0), multiple genes that play critical roles in lymphatic metastasis, such as VEGF-C, SNAI2, and MMP9 (33) (34) (35) , were significantly downregulated in BLACAT2-silenced cells ( Figure 5A ). Furthermore, immunostaining and qPCR analyses revealed that the expression of VEGF-C, SNAI2, and MMP9, at both the mRNA and the protein levels, was increased in BLACAT2-transduced cells and decreased in BLACAT2-silenced cells ( Figure 5 , B-D, and Supplemental Figure 13 , A-E). Furthermore, BLACAT2 expression levels correlated with VEGF-C expression in human bladder cancer cell lines (Supplemental Figure 14A) . Moreover, positive correlations between BLACAT2 expression and the VEGF-C, SNAI2, and MMP9 levels (P < 0.001, P < 0.001, P < 0.001, respectively) were also observed in the xenografts (Supplemental Figure 14 , B and C) and in a 140-case cohort of bladder cancer specimens ( Figure 5E and Supplemental Figure 14D ). These results indicate that BLACAT2 contributes to the upregulation of VEGF-C, SNAI2, and MMP9 in bladder cancer. BLACAT2 forms triplexes with promoter sequences of VEGF-C. Next, we focused on the molecular mechanisms of BLACAT2 in the expression of VEGF-C and performed an RNA purification assay (chromatin isolation by RNA purification [ChIRP]) to identify whether BLACAT2 directly associates with promoter sequences of VEGF-C. The ChIRP assay indicated that BLACAT2 could physiologically associate with the promoter sequences of VEGF-C ( Figure 6A ). To further identify the more precise direct binding sites between BLACAT2 and VEGF-C promoter, potential triplexforming oligos (TFOs) and corresponding triplex target sites (TTSs) were predicted with Longtarget, a web-based tool designed to predict lncRNA:DNA binding motifs and binding sites via Hoogsteen or reverse Hoogsteen base pairing (36) . Circular dichroism (CD) spectroscopy was performed using in vitro-synthesized predicted TFOs of BLACAT2 and TTSs of the VEGF-C promoter. The spectrum of BLACAT2 (33-66 nt)/VEGF-C TTS1 or TTS2 showed an obvious negative peak at approximately 210 nm and a positive peak at 270-280 nm ( Figure 6B and Supplemental Figure 15A ) when compared with the FENDRR/PITX2-positive control group and the ssRNA/PITX2-negative control group (Supplemental Figure 15 , B and C) (37) , suggesting that BLACAT2 (33-66 nt) formed triplexes with 2 binding sites of promoter sequences of VEGF-C in vitro. Moreover, BLACAT2 that was mutated at 33-66 nt failed to induce VEGF-C expression or promote HLEC tube formation and migration ( Figure 6 , C-E, and Supplemental Figure 16, A-D) . In addition, silencing of VEGF-C in BLACAT2-transduced cells only slightly decreased the expression levels of SNAI2 and MMP9, suggesting that BLACAT2-induced upregulation of SNAI2 and MMP9 did not rely on VEGF-C (Supplemental Figure 17, A and B) .Taken together, these data indicate that BLACAT2 directly forms triplexes with the promoter sequences of VEGF-C.
BLACAT2 directly binds to the WDR5 protein. Next, we performed RNA pull-down assay using biotin-labeled BLACAT2 as bait to identify BLACAT2-interacting proteins in UM-UC-3 bladder cancer cells. As shown in Figure 7A , an evident band with a molecular weight between 35 and 40 kDa was subjected to mass spectrometry (MS), which highlighted WDR5, a core component of the histone H3K4 methyltransferase complex, as a potent BLA-CAT2-interacting protein (Supplemental Figure 18) . Furthermore, both in vivo and in vitro RNA immunoprecipitation (RIP) assays revealed that BLACAT2 could interact with endogenous WDR5 in bladder cancer cells ( Figure 7B ) and with recombinant WDR5 protein ( Figure 7C ), indicating that BLACAT2 directly binds to WDR5. Moreover, a serial deletion analysis revealed that nt 100-
Figure 7. BLACAT2 directly binds to WDR5 protein and regulates VEGF-C expression. (A)
Representative image of silver-stained PAGE gels showing separated proteins that were pulled down using biotin-labeled BLACAT2. In vitro-transcribed antisense sequence of BLACAT2 was used as the nonspecific control. (B) Western blot analysis indicating that BLACAT2 associates with WDR5, as indicated by the pull-down assay with nuclear extracts or in vitrosynthesized WDR5. Antisense BLACAT2 was used as the negative control RNA in the pull-down assay. (C) RT-qPCR analysis of RNA enrichment in the RIP assay using the anti-WDR5 antibody in UM-UC-3 and 5637 bladder cancer cells. Normal IgG was used as the nonspecific control antibody. U1 and HOTTIP were used as negative and positive controls, respectively, for WDR5 binding. (D and E) Serial deletions of BLACAT2 were used in RNA pull-down assays to identify core regions of BLACAT2 that were required for physical interaction with WDR5. (F-I) Site-directed mutagenesis of 100-130 nt of BLACAT2 was performed, and the effects of BLACAT2 mutant overexpression on VEGF-C mRNA expression (F), VEGF-C secretion (G), HLEC migration (H), and HLEC tube formation (I) were evaluated. All experiments were performed with at least 3 biological replicates. Statistical significance was assessed using 1-way ANOVA followed by Dunnett's tests for multiple comparisons (C, F-I). **P < 0.01. jci.org Volume 128 Number 2 February 2018
Similarly, overexpression of BLACAT2 significantly increased, but downregulation of BLACAT2 decreased, WDR5 occupancy and H3K4 trimethylation status on SNAI2 and MMP9 promoters, whereas mut-BLACAT2 (33-66 nt) failed to induce WDR5 occupancy and H3K4 trimethylation (Supplemental Figure 22, A and B) . ChIRP analysis indicated that BLACAT2 associates with the promoter sequences of SNAI2 and MMP9 (Supplemental Figure 22C) .
VEGF-C is required for BLACAT2-induced lymphangiogenesis and LN metastasis.
Accumulating evidence has been provided that VEGF-C signaling, which plays critical roles in lymphangiogenesis and LN metastasis, may serve as a potential therapeutic target for LN-metastatic cancer (32, 34, 40, 41) . We tested to determine whether downregulation of VEGF-C could inhibit BLACAT2-induced LN metastasis. VEGF-C silencing showed more inhibitory effects on LN metastasis of BLACAT2-transduced cells relative to control cells ( Figure 9 , A and B, and Supplemental Table 3 ), resulting in longer survival times for the BLACAT2/mice relative to control mice (Supplemental Figure 23, A and B) . This result was further confirmed by the higher intratumoral and peritumoral lymphangiogenesis observed in the BLACAT2/mice relative to the control mice ( Figure 9C ). Consistently, knockdown of VEGF-C significantly inhibited BLACAT2-induced HLEC tube formation and migration, and overexpression of VEGF-C rescued the effects of BLACAT2 ablation on HLEC tube formation and migration (Supplemental BLACAT2 promotes H3K4 methylation of promoters of downstream target genes. WDR5, a core unit of human H3K4 methyltransferase complexes (38) , epigenetically modulates target gene expression by associating with methylated H3K4 to catalyze H3K4 trimethylation (39) . We sought to determine whether BALCAT2 regulated VEGF-C via WDR5-mediated H3K4 methylation. ChIP showed that BLA-CAT2 overexpression dramatically enhanced WDR5 expression and increased H3K4me3 methylation of the promoters of VEGF-C both in WDR5 hi -expressing UM-UC-3 or 5637 cells and WDR5 loexpressing T24 and RT4 cells, whereas BLACAT2 silencing drastically decreased WDR5 expression and H3K4me3 methylation of the promoters of VEGF-C (Figure 8 , E-H, and Supplemental Figure 19 , A-E). Additionally, WDR5 silencing attenuated BLACAT2-induced expression of VEGF-C-and BLACAT2-mediated lymphangiogenesis (Supplemental Figure 20, A-E) . Importantly, in SV-HUC-1 cells, an immortalized normal bladder epithelial cell line, we also observed the same effects of BLACAT2 on the upregulation of VEGF-C expression, promoting the recruitment of WDR5 and promotion of H3K4 trimethylation of the VEGF-C promoter and provoking the tube formation and migratory speed of HLECs (Supplemental Figure 21, A-F) . These results suggest that BLACAT2 might also play a role in regulating physiological lymphangiogenesis, and this mechanism was not exclusive to tumors. Therefore, our results indicate that BLACAT2 promotes H3K4 methylation of the VEGF-C promoter. peutic effect of targeting VEGF-C was then further examined in vivo. A popliteal LN metastasis model showed that treatment with the VEGF-C-neutralizing antibody (pV1006R-r) led to a significant reduction in intratumoral and peritumoral lymphatic vessel densities and decreased BLACAT2-transduced tumor burden in the LNs (Figure 10 , A-C, and Supplemental Table 3 ), which lengthened the survival times of the tumor-bearing nude mice (Supplemental Figure 27, A and B) . Taken together, these results demonstrate that VEGF-C signaling blocking reverses BLACAT2-induced lymphangiogenesis and LN metastasis in vivo ( Figure 10D ).
Discussion
Our study represents what we believe is the first analysis of lncRNA-guided epigenetic regulation of VEGF-C and lymphatic Figure 24 , A-D). However, silencing of SNAI2 only slightly reduced the metastatic capability of bladder cancer cells to LNs (Supplemental Figure 25 , A-D), suggesting that VEGF-C is essential for BLA-CAT2-induced lymphangiogenesis and LN metastasis.
Blockage of VEGF-C reverses BLACAT2-induced LN metastasis in vivo.
The VEGF-C monoclonal antibody (VGX-100) has been tested in a clinical trial for advanced or metastatic solid tumors. We examined whether VEGF-C signaling blockade using a VEGF-C-neutralizing antibody (pV1006R-r) could inhibit BLA-CAT2-induced LN metastasis. Similar to the effect of VEGF-C silencing, treatment with the VEGF-C-neutralizing antibody (pV1006R-r) significantly reduced BLACAT2-induced HLEC tube formation and motility (Supplemental Figure 26, A and B) , suggesting that deactivation of VEGF-C signaling could inhibit BLACAT2-mediated lymphangiogenesis in vitro. The thera- which VEGF-C is overexpressed in bladder cancer would provide a potential predictor for effective anti-VEGF-C treatment. Herein, we have identified an lncRNA, BLACAT2, which contributes to lymphangiogenesis and lymphatic metastasis by epigenetically upregulating VEGF-C expression in bladder cancer. Our results demonstrate that BLACAT2 directly associates with the VEGF-C promoter via formation of triplexes. Moreover, depletion of VEGF-C using siRNA or a neutralizing antibody (pV1006R-r) showed promising antitumor effects in BLACAT2-overexpressing bladder cancer by inhibiting lymphangiogenesis and LN metastasis. Therefore, our findings uncover a molecular mechanism for the lymphatic metastasis of bladder cancer and suggest that BLA-CAT2 might serve as a potential biomarker for clinical intervention in LN-metastatic bladder cancer. The role of BLACAT2 in mediating the interaction of WDR5 with multiple promoter target sequences of VEGF-C is an interesting paradigm. WDR5, a core component of the histone H3K4 methyltransferase complex, is crucial for vertebrate development and plays an important role in the self-renewal of pluripotent cells and cell differentiation (39, 55) . Multiple studies have recently documented that dysregulated WDR5 is involved in promoting cancer metastasis and chemoresistance (56, 57) , suggesting that WDR5 may serve as a therapeutic target for cancer (58) . However, WDR5 is extensively expressed in numerous cell types and plays important roles in various biological functions (39, 55, 59, 60) . Therefore, inhibition of WDR5 signaling may result in broad disturbances in normal cellular functions. Additionally, the WDR5 protein itself lacks putative DNA-binding domains, so the mechanisms through which WDR5 orients itself to its target sites across the chromatin are largely unknown. Herein, we propose a model in which BLACAT2 directly binds to WDR5 protein and recruits it to specific genomic loci through the formation of a triplex with target DNA sequences. This finding may explain why chromatin-modifying complexes can bind to numerous gene promoters in a sequence-specific manner with limited binding domains. Interestingly, a previous study has shown that point mutations on the lncRNA-binding sites of WDR5 do not affect the intrinsic catalytic activity and mixed lineage leukemia (MLL) complex assembly, but significantly abolish the binding efficiency of WDR5 to chromatin (55) , indicating that blocking the interaction between lncRNA and WDR5 may produce more specific effects than targeting WDR5 itself.
In summary, based on our results, we propose a model in which the overexpression of an lncRNA, BLACAT2, promotes LN metastasis by inducing tumor-associated lymphangiogenesis and promoting bladder cancer cell invasiveness. Moreover, analyses of TCGA and GEO databases have shown that BLACAT2 is also elevated in multiple types of human cancer, suggesting the oncogenic role of BLACAT2. Therefore, it is worth delineating the epigenetic regulatory mechanisms of the BLACAT2/WDR5 complex in relation to downstream targets in other human cancer types.
Methods
Human tissue samples and study approval. Formalin-fixed, paraffinembedded (FFPE) tissues and snap-frozen fresh bladder cancer tissues and normal adjacent tissues were obtained from patients who underwent surgery at Sun Yat-sen Memorial Hospital. All samples were confirmed by 2 pathologists. metastasis in bladder cancer. We showed that BLACAT2, an lncRNA, was markedly upregulated in human LN-metastatic bladder cancer. BLACAT2 overexpression epigenetically induced intratumoral/peritumoral lymphangiogenesis and invasion of bladder cancer through a direct interaction with WDR5, a core component of the histone H3K4 methyltransferase complex. Inhibition of lymphangiogenesis using a VEGF-C antibody markedly suppressed LN metastasis of BLACAT2-overexpressing bladder cancer cells in vivo and prolonged the survival times of tumor-bearing mice. These results provide mechanistic and translational insights into the lymphatic metastasis of bladder cancer and suggest that the inhibition of lymphangiogenesis using a VEGF-C antibody may serve as a potential tailored treatment for patients with BLACAT2-overexpressing bladder cancers.
Lymphangiogenesis, a common early metastatic event, is critical for LN metastasis and is the strongest prognostic marker of survival for patients with bladder cancer (10, 12) . Cancer cells induce the formation of new lymphatic vessels, which are characterized by discontinuous cell-cell junctions and a lack of pericytes or vascular smooth muscle cells, via secretion of lymphangiogenic growth factors with promotion of tumor cell dissemination to LNs (29, 42) . Importantly, diminishing lymphangiogenesis in vivo prevents regional LN metastasis and prolongs animal survival times in studies of other cancer types (43, 44) . Herein, our results show that downregulation of BLACAT2 plays dual antilymphatic metastasis roles, including prevention of lymphangiogenesis and inhibition of cell invasiveness, suggesting that BLA-CAT2 may serve as a potential target for intervention in bladder cancer. To our knowledge, this is the first report to show that overexpression of an lncRNA closely correlates with lymphangiogenesis and LN metastasis in bladder cancer and predicts a poor prognosis of patients with MIBC.
Recently, small molecules that were designed to target the folded structure of the oncogenic noncoding RNA have shown significant antitumor effects in vivo by selectively modulating noncoding RNAs in cancer cells with no effects in normal cells (45) . Additionally, locked nucleic acid (LNA) can serve as a therapeutic agent that specifically targets lncRNAs in vivo (46) . In the future, inhibition of tumor-induced lymphangiogenesis and cancer invasiveness via small molecules that specifically target BLACAT2 therefore might be a potential therapeutic target of human cancer.
VEGF-C, a lymphatic vessel-specific growth factor, is upregulated in various human cancers, including bladder cancer (47) (48) (49) , and has been shown to play critical roles in disrupting the endothelial lymphatic barrier (50, 51) and facilitating lymphatic invasion of cancer cells, ultimately resulting in significantly enhanced lymphatic metastasis and cancer treatment failure (52) . Blocking the VEGF-C/VEGFR-3 lymphangiogenic axis significantly reduces the rate of LN metastasis in multiple cancer-bearing experimental mouse models (17, 44, 53) . Interestingly, several studies have suggested that the inhibition of VEGF-C not only decreases metastatic lesions within LNs in mouse models, but also suppresses metastatic cancer dissemination from LNs to distant organs (9, 15, 41, 54) . Moreover, a VEGF-C monoclonal antibody (VGX-100) has been tested in a phase I clinical trial for the treatment of advanced or metastatic solid tumors (ClinicalTrials.gov NCT01514123). Therefore, exploring the precise molecular mechanism through jci.org Volume 128 Number 2 February 2018 RIP and ChIP. RIP assays were performed using the EZ-Magna RIP Kit (Millipore) and ChIP experiments were performed using the EZ-Magna ChIP A/G Kit (Millipore) at 4°C as previously described (20) . Briefly, for the RIP assays, 1 × 10 7 cells were harvested and lysed with RIP lysis buffer with 1 freeze-thaw cycle. Cell extracts were coimmunoprecipitated using anti-WDR5 (Abcam, ChIP grade) and the retrieved RNA was quantified by RT-qPCR. Normal mouse IgG was used as the negative control. For RT-qPCR analysis, HOTTIP was used as the positive control and U1 RNA was used as a nonspecific control. For each ChIP assay, 1 × 10 6 cells were fixed in 1% formaldehyde at room temperature for 10 minutes and the nucleus was isolated with nuclear lysis buffer (Millipore) supplemented with a protease inhibitor cocktail (Millipore). Chromatin DNA was sonicated and sheared to a length between 200 bp and 1,000 bp. The sheared chromatin was immunoprecipitated at 4°C overnight using anti-WDR5 (Abcam, ChIP grade) or anti-H3K4me3 (Abcam, ChIP grade). Normal mouse IgG was used as the negative control, and anti-RNA pol II (Millipore) was used as a technical control antibody. Primers for ChIP-qPCR are listed in Supplemental Table 5 .
Chromatin isolation by RNA purification. ChIRP was performed as previously described (63) . Briefly, each probe was designed using a single-molecule FISH online designer (63), biotin-labeled at its 3′ terminus, and divided into odd or even groups. Next, 2 × 10 7 cells
were used for each ChIRP assay and crosslinked in 1% formaldehyde at room temperature for 10 minutes. The cells were lysed, sheared to 100-500 bp fragments with mean sizes of approximately 150-200 bp at 4°C, and hybridized with probes in a hybridization oven. The probes used in the ChIRP assay are listed in Supplemental Table 6 . Accession numbers. The accession numbers for the full-length human BLACAT2 sequence were submitted to GenBank (MF435912, MF435913, MF435914). All primary data from microarray analysis and NGS data were deposited in the NCBI's Gene Expression Omnibus database (GSE100926, GSE101287).
Statistics. Quantitative data are presented as mean ± SD from at least 3 independent experiments. Unless otherwise noted, differences between 2 groups were analyzed with the unpaired/paired Student's t test using SPSS 13.0. The Mann-Whitney U test was used for independent samples when the population could not be assumed to be normally distributed. When more than 2 treatments were compared, 1-way ANOVA followed by Dunnett's multiple comparisons tests was performed. The correlation coefficient between BLACAT2 expression and clinicopathological characteristics was calculated using the SPSS 13.0 Spearman's and Kendall's correlation. Kaplan-Meier curves of metastasis-free survival or overall survival were compared with the log-rank test. All tests were 2 sided. Differences were considered statistically significant at P < 0.05.
Study approval. Ethical consent was given by the Sun Yat-sen University Committee for Ethical Review of Research Involving Human Subjects. The use of human bladder cancer tissue specimens was evaluated and approved by the Ethical Committee of Sun Yat-sen Memorial Hospital, and written informed consent was obtained from all participants or their appropriate surrogates. All animal studies were conducted with the approval of the Sun Yat-sen University Institutional Animal Care and Use Committee and were performed in accordance with established guidelines.
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WH, JH and TL participated in the study design; GZ, NJ and CC carried out the in vitro and in vivo experiments and data analMicroarray and data analysis, cell culture and transfection, RNA isolation, RT-qPCR analysis, nuclear fractionation, cell motility, invasion assay, and immunoblots. Microarray and data analyses, cell culture and transfections, RNA isolations, RT-qPCR analysis, nuclear fractionations, cell motility and invasion assays, and immunoblots were performed following standard protocols as previously reported (20) . All details are also described in the Supplemental Materials and Methods section. The SurePrint G3 Human Gene Expression Microarray (catalog G4851B, Agilent) was used for the microarray analysis. Patient characteristics are described in Supplemental Table 1 . All bladder cancer cell lines were purchased from ATCC. The sequences of siRNA oligos are listed in Supplemental Table 4 . The sequences of all primers used in this study are shown in Supplemental Table 5 . For the overall and metastasis-free survival analyses, the median expression level of BLACAT2 determined by RT-qPCR was used as a cutoff value.
ISH and immunohistochemistry analysis. BLACAT2 expression was also examined using ISH in FFPE samples, as previously described (61) . Briefly, after dewaxing and rehydration, the samples were digested with 20 μg/ml proteinase K (Roche), fixed in 4% paraformaldehyde, hybridized with a double (5′ and 3′) digoxin-labeled (DIGlabeled) LNA-modified BLACAT2 probe (Exiqon) at 42°C overnight, and subsequently incubated overnight at 4°C with anti-DIG monoclonal antibody conjugated to alkaline phosphatase (Roche, catalog 11093274910). After staining with nitro blue tetrazolium/5-bromo-4-chloro-3-indolylphosphate (Roche), the sections were mounted and observed. A double (5′ and 3′) DIG-labeled scrambled probe was used as the negative control, and double (5′ and 3′) DIG-labeled probes against U6 snRNA (nuclear staining) and β-actin (cytoplasmic staining) were used as technical positive controls. The sequences of all the probes used in ISH are shown in Supplemental Table 6 .
The immunohistochemistry analyses were performed as previously described (62) . The degree of ISH and immunohistochemistry (IHC) in the FFPE samples was reviewed and scored by 2 independent pathologists. The proportion of tumor cells with positive staining was designated as follows: 0, no positive tumor cells; 1, 0%-10% positive tumor cells; 2, 10%-30% positive tumor cells; 3, 30%-70% positive tumor cells; and 4, more than 70% positive tumor cells. The staining intensity was graded as follows: 1, no staining; 2, weak staining (light yellow for IHC, light blue for ISH); 3, moderate staining (yellow brown for IHC, moderate blue for ISH); and 4, strong staining (brown for IHC, strong blue for ISH). The staining index (SI) was calculated by multiplying the proportion of positive tumor cells and the staining intensity score, with possible scores of 0, 1, 2, 3, 4, 6, 8, 9, 12, and 16. ISH and IHC were independently analyzed by 2 experienced pathologists who were blinded to the tissue information.
Popliteal LN metastasis assay. BALB/c nude mice (4 to 5 weeks old) were purchased from the Experimental Animal Center, Sun Yat-sen University. Eight mice were included in each group, and lentivirustransduced UM-UC-3 cells (5 × 10 5 cells) that stably expressed firefly luciferase were inoculated into the footpads. For the VEGF-C-treatment assays, a nonimmune control IgG (50 ng/ml in HBSS) or neutralizing antibody against VEGF-C (pV1006R-r, 50 ng/ml in HBSS) was intravenously injected. The primary tumors and popliteal LNs were enucleated and embedded in paraffin. The LN volumes were calculated using the following formula: LN volume(mm 
